●大湖水殖股份有限公司（以下简称"公司"）股票于 2023 年 8 月 23 日、24 日连续 2 个交易日内收盘价涨幅偏离值累计超过 20%， 根据《上海证券交易所股票上市规则》的有关规定，属于股票交易异 常波动情形。 ●经公司自查，并书面征询公司控股股东、实际控制人，截止本 公告披露日，除了已经披露的事项，不存在应披露而未披露的重大事 项。 证券代码：600257 证券简称：大湖股份 公告编号：2023-048 大湖水殖股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： 一、股票交易异常波动的具体情况 经公司自查并向公司控股股东及实际控制人书面征询，核实公司 控股股东、实际控制人不存在应披露而未披露的引起股票交易异常波 公司股票于 2023 年 8 月 23 日、24 日连续 2 个交易日内收盘价 涨幅偏离值累计超过 20%，根据《上海证券交易所股票上市规则》的 有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 动的重大事项 ...

湖南启元律师事务所 关于大湖水殖股份有限公司 2023年第三次临时股东大会的 法律意见书 二零二三年八月七日 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 等法律、法规和规范性文件以及《大湖水殖股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，我们依法审核了公司提供的下列资料： 1、刊登在 2023 年 7 月 22 日上海证券交易所网站（http://www.sse.com.cn/） 上的公司第九届董事会第二次会议决议公告（以下简称"《董事会决议》"）及刊 登在 2023 年 7 月 22 日上海证券交易所网站（http://www.sse.com.cn/）上的关于 召开公司 2023 年第三次临时股东大会的通知（以下简称"《股东大会通知》"）； 为出具法律意见书，本律师特作声明如下： 2、出席会议股东或其代理人的资格、身份证明文件等； 3、公司本次股东大会股权登记日的股东名册、出席现场会议的股东的到会 登记记录及凭证资料； 4、公司本次股东大会会议文件。 湖南 ...

Financial Performance - The company's operating revenue for 2021 was approximately CNY 1.29 billion, representing a 37.99% increase compared to CNY 936.52 million in 2020[21]. - The net profit attributable to shareholders for 2021 was a loss of approximately CNY 180.12 million, a decrease of 4,417.79% compared to a profit of CNY 4.17 million in 2020[22]. - The net cash flow from operating activities for 2021 was approximately CNY 96.42 million, a significant increase of 387.10% compared to a negative cash flow of CNY 33.58 million in 2020[22]. - Total assets at the end of 2021 were approximately CNY 2.34 billion, an increase of 18.89% from CNY 1.97 billion at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 18.4% to approximately CNY 949.43 million at the end of 2021, down from CNY 1.16 billion at the end of 2020[22]. - The basic and diluted earnings per share for 2021 were both -0.37 RMB, a decrease of 4,352.87 percentage points compared to the previous year[23]. - The weighted average return on equity was -17.20%, down 17.56 percentage points from the previous year[23]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥96,420,908.67, compared to a negative cash flow of ¥33,584,944.13 in the previous year, marking a 387.10% improvement[55]. - The company reported a net loss of CNY 147,629,932.28 in retained earnings, compared to a profit of CNY 42,924,427.31 in the previous year[174]. - The total comprehensive loss for 2021 was approximately -¥197.95 million, compared to a comprehensive income of ¥21.27 million in 2020[180]. Business Segments and Operations - The company operates two main business segments: health product production and sales, and health medical service management, focusing on synergistic development[45]. - The aquaculture division emphasized high-quality breeding and the development of organic fresh food products[33]. - The revenue from the aquaculture segment accounted for 58.65% of total revenue, representing a year-on-year growth of 24.36%, with frozen aquatic products sales increasing by 280.16%[35]. - The health liquor segment's revenue share was 10.86%, showing a significant year-on-year increase of 49.95%[36]. - The health medical services segment's revenue share reached 16.74%, with a remarkable year-on-year growth of 530.07%[38]. - The company is focusing on the development of a "medical, nursing, and rehabilitation" integrated model in its health medical services[38]. - The company has established partnerships with well-known medical institutions to enhance its brand influence and service quality[38]. - The company is actively pursuing a strategic transformation towards the health industry, integrating health products and services[38]. - The company has established a comprehensive freshwater fish industry chain, emphasizing quality management and obtaining multiple certifications, including ISO9001 and organic product certification[46]. Market and Competitive Landscape - The company faces various operational risks, including market competition and food safety risks, as detailed in the management discussion section[9]. - The company faces competition risks in the market for its natural fish products, which have lower yields compared to pond-raised fish[78]. - The company faces risks in the white liquor industry due to intense competition and the potential market squeeze from national brands, as its products are categorized as regional brands[79]. - The demand for high-end liquor products is increasing, with a significant shift towards premium brands due to rising consumer health awareness and disposable income[44]. - The rehabilitation medical industry in China is projected to grow rapidly, with an expected market size exceeding 220 billion yuan by 2025, reflecting a compound annual growth rate of 20.60% from 2016 to 2025[44]. Governance and Management - The company held one annual general meeting and two extraordinary general meetings during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[83]. - The board of directors consists of five members, including two independent directors, and has established four specialized committees to enhance governance and oversight[84]. - The total remuneration for the board members and senior management during the reporting period amounted to 4.5176 million yuan[89]. - The company has maintained a stable management team with no changes in shareholding among directors and supervisors[89]. - The company has a diverse management background with members having experience in various sectors including finance and project management[90]. - The company has established specialized committees within the board, including an audit committee and a strategic committee[103]. Financial Position and Assets - The company's total assets amounted to RMB 1,671,235,752.66 in 2021, compared to RMB 1,632,143,258.27 in 2020, reflecting a growth of 2.4%[177]. - Total liabilities reached CNY 1,265,140,435.82, compared to CNY 669,327,720.34 in 2020, reflecting a substantial increase of around 89%[174]. - The company's total equity decreased to RMB 1,017,750,548.45 in 2021 from RMB 1,151,086,977.23 in 2020, a decline of 11.6%[177]. - The company has pledged 368,078,828.90 RMB of subsidiary net assets to secure a bank loan for acquiring 60% of Dongfang Huakang Medical Management Co., Ltd.[71]. - The company has engaged in cash asset management, with a total of ¥20,000,000 in bank fixed-term wealth management and ¥30,000,000 in structured deposits[153]. Strategic Initiatives and Future Outlook - The company plans to enhance brand marketing and product innovation to strengthen its market position in the health food sector[33]. - The company is implementing a dual-channel marketing strategy, combining online and offline sales, and targeting both B2B and B2C markets[35]. - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[196]. - The company expects net profits for 2022, 2023, 2024, and 2025 to be CNY 45 million, CNY 60 million, CNY 80 million, and CNY 80 million respectively, totaling CNY 245 million over five years[128]. Social Responsibility and Environmental Impact - The company has donated a total of 268,200 CNY to support rural revitalization projects, with specific contributions of 150,000 CNY to the Yanglouping Village project and 100,000 CNY to the Dongliuxi Village project[122]. - The company emphasizes environmental protection by adopting an ecological breeding model that reduces carbon emissions and promotes sustainable development[117]. - The company has released over 100 million high-quality fish fry to protect the aquatic ecological environment over the past decade[120].

Financial Performance - In 2020, the company achieved a net profit attributable to shareholders of RMB 4,171,552.73, a significant recovery from a loss of RMB 131,096,174.57 in 2019, marking a 103.18% increase[5] - Total operating revenue for 2020 was RMB 936,517,809.75, down 15.82% from RMB 1,112,490,033.62 in 2019[21] - The basic earnings per share improved to RMB 0.0087 in 2020, a recovery from a loss of RMB 0.2724 per share in 2019, representing an increase of 103.19 percentage points[22] - The company reported a negative cash flow from operating activities of RMB 33,584,944.13 in 2020, a decline of 184.91% compared to a positive cash flow of RMB 39,555,297.00 in 2019[21] - The weighted average return on net assets was 0.36% in 2020, up from -10.66% in 2019, reflecting a significant improvement[22] - The company reported a non-recurring profit of CNY 33,341,166.12 in 2020, compared to a loss of CNY 70,257,800.78 in 2019[26] - The company achieved operating revenue of ¥936,517,809.75, a decrease of 15.82% compared to the previous year[46] - The net profit attributable to shareholders was ¥4,171,552.73, reflecting a significant decline in profitability[45] - Operating costs decreased by 19.47% to ¥704,915,049.32, indicating improved cost management[46] Assets and Liabilities - The company's total assets increased by 15.46% to RMB 1,968,514,403.28 at the end of 2020, compared to RMB 1,704,978,026.25 at the end of 2019[21] - The company’s net assets attributable to shareholders increased slightly by 0.39% to RMB 1,163,502,412.71 at the end of 2020[21] - Total liabilities increased to RMB 669,327,720.34 in 2020 from RMB 516,265,908.49 in 2019, which is an increase of approximately 29.6%[168] - The company's equity attributable to shareholders reached RMB 1,163,502,412.71 in 2020, slightly up from RMB 1,159,004,376.86 in 2019, showing a marginal increase of about 0.4%[169] - The cash and cash equivalents decreased to RMB 220,758,727.54 in 2020 from RMB 313,833,938.93 in 2019, a decline of approximately 29.6%[167] Investments and Acquisitions - The company has expanded its healthcare services through the acquisition of Dongfang Huakang Medical Management Co., which focuses on rehabilitation and nursing services[32] - The company acquired an 8% stake in Dongfang Huakang for 50 million yuan and later increased its stake to 60% through additional investments totaling 25 million yuan[63] - The company completed the acquisition of 60% equity in Dongfang Huakang, with a total cash investment of RMB 25 million[96] - The goodwill generated from the acquisition of Dongfang Huakang amounted to RMB 189.204 million, with no impairment indicators identified[89] Market and Industry Trends - The white liquor segment is expected to benefit from the ongoing consumption upgrade trend despite the impact of the pandemic on social consumption[34] - The freshwater aquaculture industry is projected to maintain stable growth, supported by government policies promoting green development and quality improvement[33] - The rehabilitation medical service sector in China has a compound annual growth rate (CAGR) of 10.2% for service visits, driven by an aging population and increased chronic disease prevalence[35] - The domestic market for aquatic products is shifting towards convenient and quick-prepared products, driven by changes in consumer habits due to the COVID-19 pandemic[70] Social Responsibility and Community Engagement - The company is involved in poverty alleviation efforts, providing financial support for infrastructure and agricultural development in Gao Feng Village[110] - The company invested a total of 16.35 million RMB in poverty alleviation efforts, helping 16 registered impoverished individuals to escape poverty[112] - The company continues to engage in social responsibility initiatives, including environmental protection and community support, while pursuing economic benefits[114] Operational Efficiency and Management - The company has established a comprehensive rehabilitation medical system, but the overall scale remains small compared to developed countries, indicating significant growth opportunities[35] - The company has established a strategic compensation policy that aligns employee remuneration with performance management, ensuring a reasonable match between corporate benefits and employee earnings[140] - The company has undergone changes in senior management, including the appointment of new deputy general managers and the election of independent directors[137] Risks and Challenges - The company has disclosed potential risks in its operations, which are detailed in the report, urging investors to be cautious[7] - Rising operational costs, including labor and procurement, pose a risk to profitability, which the company plans to manage through refined management and brand enhancement[78] - The company faces competition from pond-raised fish, which have higher yields, but anticipates that the demand for its naturally raised fish will grow as consumer preferences shift towards healthier options[78]

Financial Performance - The company's operating revenue for 2022 was CNY 1,094,712,820.42, a decrease of 15.29% compared to CNY 1,292,312,436.98 in 2021[23] - The net profit attributable to shareholders of the listed company was a loss of CNY 71,495,117.40, an improvement of 60.31% from a loss of CNY 180,118,858.50 in the previous year[23] - The net cash flow from operating activities was CNY 97,866,143.08, showing a slight increase of 1.50% compared to CNY 96,420,908.67 in 2021[23] - Total assets at the end of 2022 were CNY 2,161,876,319.04, a decrease of 7.63% from CNY 2,340,424,356.56 at the end of 2021[23] - The net assets attributable to shareholders of the listed company decreased by 7.34% to CNY 879,723,654.23 from CNY 949,434,742.91 in 2021[23] - Basic earnings per share improved by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - Diluted earnings per share also increased by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - The weighted average return on equity improved by 9.38 percentage points from -17.2% in 2021 to -7.82% in 2022[24] - The company reported a net loss of CNY 219,125,049.68 in 2022, compared to a net loss of CNY 147,629,932.28 in 2021, indicating a worsening of approximately 48.4%[195] Business Operations - The company faced a decline in revenue from its main business, with a decrease of 15.51% in the revenue excluding non-main business income[23] - The company is focusing on health products and health services, aiming to upgrade to a comprehensive health industry[33] - The aquaculture division is enhancing brand marketing and optimizing product structure based on high-quality seedling breeding and ecological balance[33] - The company is committed to ecological aquaculture, promoting the production of safe and healthy organic freshwater products[33] - The company plans to continue expanding its sales channels and improving its product structure in the health sector[33] - The revenue from frozen and chilled products (including prepared dishes) increased by approximately 13% year-on-year in 2022[34] - The company has established a pre-prepared dish industrial park with a total area of 46,700 square meters, including a cold storage area of over 1,900 square meters, expected to increase production capacity by 15,700 tons[34] - The company has adjusted its product structure to focus on the development of sauce-flavored liquor, with an increasing proportion of mid-range and high-end series liquor products[37] - The health medical service division has implemented a quality management monitoring system to enhance medical service quality and improve hospital reputation[38] - The company has established a rehabilitation hospital and nursing home in Hangzhou, which officially opened in August 2022, aligning with national health strategies[40] Market Trends and Opportunities - The pre-made dishes market in China is expected to exceed 800 billion yuan by 2025, with the pre-made dish market for sauerkraut fish projected to reach 1.69 billion yuan, highlighting the growth potential in the aquatic pre-made dish sector[46] - The aquatic pre-made dish market is becoming a new growth point for the aquatic industry, driven by changing consumer habits and the demand for convenient, healthy food options[46] - The number of rehabilitation medical discharges in China reached 4.42 million in 2021, with a five-year compound growth rate of 8.81%, indicating a growing demand for rehabilitation services[50] - The Chinese rehabilitation medical market is expected to exceed 220 billion yuan by 2025, driven by an aging population and increasing rehabilitation needs[50] Corporate Governance - The company has established a governance structure that includes a board of directors with 5 members, including 2 independent directors[91] - The company held 9 board meetings and 5 supervisory meetings during the reporting period[92] - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, with a total of 22 proposals reviewed and approved[94] - The total pre-tax remuneration for the chairman and general manager was CNY 798,700, while the vice chairman received CNY 332,200[96] - The company has maintained a consistent management team with no changes in shareholding reported for the year[96] Financial Health and Investments - The company's cash and cash equivalents decreased by 32.10% to ¥231,449,101.93, primarily due to the repayment of short-term loans[78] - The company reported a significant reduction in short-term borrowings by 16.04% to ¥263,806,070.52, reflecting repayment efforts[79] - The company has engaged in bank wealth management with a total amount of 94,260,000 RMB, with no overdue amounts[166] - The company has a rental payment obligation totaling 342,873,165.3 RMB, after deducting payments made in 2021 and 2022[163] - The company has ongoing guarantees for rental payments amounting to 313,574,275.7 RMB for two hospitals[162] Research and Development - Research and development expenses increased by 160.99% to CNY 947.66 thousand, reflecting a focus on innovation[61] - Total R&D investment accounted for 0.08% of operating revenue, with all R&D expenses being expensed rather than capitalized[74] - The company has implemented a diversified training program to enhance employee skills and core competitiveness, resulting in a significant increase in the number of employees obtaining intermediate and senior professional titles in 2022[120] Social Responsibility - The company contributed a total of CNY 25.64 million to various charitable projects, including CNY 17 million in cash donations and CNY 8.64 million in material donations[129] - The total donation for rural revitalization and poverty alleviation projects amounted to CNY 32.65 million, with specific contributions of CNY 20 million to Yanglouping Village and CNY 10 million to Dongxi West Village[130] - The company has actively participated in social responsibility initiatives, including environmental protection and community support[128] Strategic Changes and Future Plans - The company has acknowledged potential risks in its future plans and development strategies, advising investors to be cautious[6] - The company plans to issue non-public A-shares in 2022, with a feasibility analysis for the use of raised funds[108] - The company is focusing on new product development and technological advancements to drive future growth[171] - The overall financial performance indicates a positive outlook for the upcoming fiscal year, with strategic initiatives in place[171]

证券代码：600257 证券简称：大湖股份 公告编号：2023-020 大湖水殖股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 关于召开 2022 年度业绩说明会的公告 重要内容提示： 会议召开时间：2023 年 06 月 09 日(星期五)下午 15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址:http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络视频和网络文字互动 投资者可于 2023 年 06 月 02 日(星期五)至 06 月 08 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏 目或通过公司邮箱 925286482@qq.com 进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 大湖水殖股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日披露公司 2022 年年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,094,712,820.42, a decrease of 15.29% compared to CNY 1,292,312,436.98 in 2021[23] - The net profit attributable to shareholders of the listed company was a loss of CNY 71,495,117.40, an improvement of 60.31% from a loss of CNY 180,118,858.50 in the previous year[23] - The net cash flow from operating activities was CNY 97,866,143.08, showing a slight increase of 1.50% compared to CNY 96,420,908.67 in 2021[23] - Total assets at the end of 2022 were CNY 2,161,876,319.04, down 7.63% from CNY 2,340,424,356.56 at the end of 2021[23] - The net assets attributable to shareholders of the listed company decreased by 7.34% to CNY 879,723,654.23 from CNY 949,434,742.91 in 2021[23] - Basic earnings per share improved by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - Diluted earnings per share also increased by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - The weighted average return on equity improved by 9.38 percentage points from -17.2% in 2021 to -7.82% in 2022[24] - The company reported a net loss of CNY 219,125,049.68 for the year, compared to a loss of CNY 147,629,932.28 in the previous year, indicating a worsening of approximately 48.4%[192] - The company reported a total revenue of $1.06 billion from offline sales, down 15.80% year-over-year, with a gross margin of 23.19%, decreasing by 3.94 percentage points[64] Revenue Breakdown - The company faced a decrease in revenue from its main business, with a reported figure of CNY 1,085,246,159.37, down 15.51% from CNY 1,284,524,215.94 in the previous year[23] - Total revenue for Q1 2022 was 219,017,105.58 CNY, while Q2 was 320,603,898.69 CNY, Q3 was 288,475,793.47 CNY, and Q4 was 266,616,022.68 CNY[26] - The total revenue from the medical services segment was $222.95 million, with a gross margin of 28.26%, reflecting a year-over-year increase of 3.66%[64] - The total revenue from online sales was $23.38 million, with a gross margin of 39.71%, showing a slight decrease of 0.32% year-over-year[64] - The company’s total revenue from the central-south region was $732.74 million, down 21.99% year-over-year, with a gross margin of 23.55%, a decrease of 1.26 percentage points[64] - The total revenue from the east China region was $279.79 million, reflecting a year-over-year increase of 14.18%, with a gross margin of 25.68%, down 13.94 percentage points[64] Cost Management - The company reported a 10.84% reduction in operating costs, totaling CNY 835,395,069.46[61] - The company reported a significant decrease in selling expenses, which fell to CNY 59,120,971.80 in 2022 from CNY 95,535,225.90 in 2021, a reduction of approximately 38%[200] - Total operating costs for 2022 were CNY 1,100,011,040.37, down from CNY 1,244,399,571.64 in 2021, reflecting a reduction of about 11.6%[199] Investments and R&D - Research and development expenses increased by 160.99%, reaching CNY 947,656.36[61] - Research and development expenses increased to CNY 947,656.36 in 2022 from CNY 363,103.11 in 2021, representing a growth of approximately 161.5%[200] Governance and Compliance - The company maintained a robust governance structure, adhering to relevant laws and regulations to protect shareholder rights[88] - The board of directors convened 9 meetings, ensuring compliance with governance standards and effective oversight[89] - The company held 1 annual and 2 temporary shareholder meetings during the reporting period, with all resolutions passed without any objections[90] Market and Strategic Initiatives - The company focused on optimizing product structure and enhancing sales channels to support its health product and health service strategy[33] - The aquaculture division emphasized ecological breeding and sustainable practices to produce high-quality organic freshwater products[33] - The company aims to upgrade and transform into a comprehensive health industry by integrating health products and services[33] - The company has established a pre-prepared dish industrial park with a total area of 46,700 square meters, including a cold storage area of over 1,900 square meters, expected to increase production capacity by 15,700 tons[34] Employee and Management - The total number of employees in the parent company is 211, while the main subsidiaries employ 1,480, resulting in a total of 1,691 employees[112] - The total remuneration for all directors, supervisors, and senior management was 4.286 million yuan[102] - The company emphasizes the importance of grassroots employee compensation, directing performance rewards primarily to frontline staff[114] Environmental and Social Responsibility - The company invested 263.49 million yuan in environmental protection during the reporting period[122] - The company has contributed a total of 32.65 million yuan to poverty alleviation and rural revitalization projects, including 20 million yuan to support a specific village[127] - The company is committed to ecological sustainability in its operations, aligning with government initiatives for high-quality green development[169] Acquisitions and Partnerships - The company acquired 60% equity in Dongfang Huakang for a total cash consideration of 250 million RMB, including 50 million RMB for 8% equity and 200 million RMB for 32% equity, along with a capital increase of 12.5 million RMB[133] - The company and its subsidiary invested RMB 27 million each to hold 90% equity in two newly established hospitals, Shanghai Jinxian Rehabilitation Hospital and Shanghai Fengxiang Nursing Home[150] Future Outlook - The company has plans for market expansion and new product development in the upcoming fiscal year[168] - The overall financial performance indicates a stable growth trajectory, with a focus on enhancing user engagement and product offerings[168]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 250,086,468.74, representing a year-on-year increase of 14.19%[4] - The net profit attributable to shareholders was a loss of CNY 9,137,404.94, which is a deterioration of 30.75% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was a loss of CNY 11,199,650.32, reflecting a decline of 25.43% year-on-year[4] - The net loss for Q1 2023 was CNY 1,962,582.84, compared to a net loss of CNY 1,000,000.00 in Q1 2022, indicating a worsening of financial performance[18] - The net profit for Q1 2023 was -7,235,139.22 RMB, compared to -13,072,794.39 RMB in Q1 2022, showing an improvement of approximately 44.5% year-over-year[19] - The total operating profit for Q1 2023 was -1,087,630.25 RMB, a significant decrease from -8,458,869.94 RMB in the same period last year[19] - The company reported a total revenue from sales of goods and services of 286,790,049.11 RMB, up from 265,275,237.37 RMB in Q1 2022, representing a growth of approximately 8.5%[21] - The basic and diluted earnings per share for Q1 2023 were both -0.0190 RMB, an improvement from -0.0274 RMB in Q1 2022[20] - The total comprehensive income attributable to the parent company for Q1 2023 was -9,137,404.94 RMB, an improvement from -13,194,146.45 RMB in Q1 2022[20] Cash Flow and Assets - The net cash flow from operating activities was CNY 9,706,948.72[4] - The company reported a significant decrease in cash flow from investment activities, down 64.59% due to no financial investments made during the period[6] - Cash flow from operating activities generated a net inflow of 9,706,948.72 RMB, a recovery from a net outflow of -57,552,807.28 RMB in Q1 2022[22] - The net cash flow from financing activities was 11,351,611.04 RMB, a turnaround from a net outflow of -36,112,966.30 RMB in Q1 2022[22] - The company's cash and cash equivalents as of March 31, 2023, amounted to CNY 245,208,241.35, compared to CNY 231,449,101.93 at the end of 2022, representing a growth of 5.5%[13] - The cash and cash equivalents at the end of Q1 2023 were 244,771,151.84 RMB, compared to 215,064,915.34 RMB at the end of Q1 2022, indicating an increase of about 13.8%[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,159,956,485.13, a slight decrease of 0.09% from the end of the previous year[5] - The total assets of the company as of March 31, 2023, were CNY 2,159,956,485.13, slightly down from CNY 2,161,876,319.04 at the end of 2022[15] - The total liabilities increased to CNY 1,166,712,784.79 as of March 31, 2023, compared to CNY 1,160,504,202.31 at the end of 2022, reflecting a rise of 0.5%[15] - Shareholders' equity attributable to the parent company was CNY 869,692,972.12, down 1.14% from the previous year-end[5] - The company reported a decrease in retained earnings, with a balance of CNY -228,262,454.62 as of March 31, 2023, compared to CNY -219,125,049.68 at the end of 2022[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 52,169[8] - The largest shareholder, Tibet Hongshan Technology Development Co., Ltd., held 21.74% of the shares, with 51,340,000 shares pledged[8] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 252,049,050.98, up from CNY 227,658,563.61 in Q1 2022, reflecting a year-over-year increase of 10.7%[18] - The company incurred total operating expenses of 298,300,099.05 RMB in Q1 2023, down from 340,396,564.94 RMB in Q1 2022, reflecting a reduction of approximately 12.4%[22] - Research and development expenses for Q1 2023 were CNY 214,447.17, significantly higher than CNY 57,003.97 in Q1 2022, marking an increase of 276.5%[18] Other Financial Metrics - The weighted average return on equity was -1.04%, an increase of 0.36 percentage points compared to the previous year[4] - The company recorded an asset disposal loss of 2,440.00 RMB in Q1 2023, compared to a loss of 17,431.33 RMB in Q1 2022[19] - Accounts receivable increased to CNY 148,235,179.44 as of March 31, 2023, from CNY 128,934,683.31 at the end of 2022, indicating a rise of 14.9%[13] - Inventory decreased to CNY 493,205,864.19 as of March 31, 2023, down from CNY 520,826,478.84 at the end of 2022, a decline of 5.3%[13]

2022 年第三季度报告 证券代码：600257 证券简称：大湖股份 大湖水殖股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比 上年同期增减变动 | | --- | --- | --- | --- | --- | | | | 增减变动幅度(%) | | | | | | | | 幅度(%) | | 营业收入 | 288,475,793.47 | -17.39 | 828,096,797.74 | -11.52 | | 归属 ...

证券代码：600257 证券简称：大湖股份 公告编号：2022-048 大湖水殖股份有限公司 关于参加 2022 年湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，使广大投资者能更深入 全面地了解大湖水殖股份有限公司（以下简称"公司"）情况，公 司将参加由中国证券监督管理委员会湖南监管局、湖南省上市公 司协会和深圳市全景网络有限公司联合举办的"湖南辖区上市公 司投资者网上接待日活动"，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公 司提供的互联网平台举行，投资者可以登录"全景·路演天下" 网站（http://rs.p5w.net），参与公司本次投资者网上接待日活 动，活动时间为 2022 年 9 月 29 日（星期四）下午 14:00 至 17:00， 下午 15:30 开始上市公司与投资者网上互动环节。 届时公司董事会秘书及证券事务代表将通过网络文字交流 形式与投资者进行沟通与交流。欢迎广大投资者积极参与。 ...